07.05.2021 • News

Azelis Boosts US Life Sciences with Vigon Buy

Azelis has entered into an agreement to buy US-based Vigon International, expanding its footprint in the life sciences sector. Financial details of the transaction expected to close in the second quarter of 2021 were not disclosed.

Based in East Stroudsburg, Pennsylvania, Vigon is a specialty distributor and manufacturer of ingredients for the flavors, fragrances and cosmetics markets. Its portfolio includes flavors, natural and synthetic aroma chemicals, actives, functional ingredients and essential oils. The company has 120 employees and serves more than 1,000 customers across the three market segments.

“As a leader in the US flavors and fragrances market segments, Vigon provides Azelis the impetus for geographic expansion in these markets across North America, as well as a platform for future acquisitions of complementary businesses in the food ingredients segments,” said Azelis Americas CEO and president Frank Bergonzi. “Vigon’s co-manufacturing and blending capabilities provide us an added value proposition that we can leverage to better serve our principals and customers.”

Azelis Americas is headquartered in Westport, Connecticut and serves suppliers and customers in the US, Canada and Mexico. The business was formerly known as Koda Distribution Group until it was acquired by Azelis in December 2015.

Author: Elaine Burridge, Freelance Journalist

Azelis is buying US-based Vigon International, expanding its footprint in the...
Azelis is buying US-based Vigon International, expanding its footprint in the life sciences sector. Based in East Stroudsburg, Pennsylvania, Vigon is a specialty distributor and manufacturer of ingredients for flavors, fragrances and cosmetics. The deal should close in Q2 2021. (c) Azelis

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.